MetaCap

Latigo Biotherapeutics SEC Filings

NASDAQ: LTGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

16.00+1.21 (+8.18%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Latigo Biotherapeutics filing overview

This page lists 17 recent SEC filings by Latigo Biotherapeutics (LTGO), including 6 4, 3 SCHEDULE 13G, 2 8-K, 2 S-1/A. The most recent quarterly report (10-Q) was filed on Sep 3, 2026. The latest current report (8-K), used to disclose material events such as earnings releases and executive changes, was filed on Sep 3, 2026.

Form 10-K is the audited annual report, 10-Q the quarterly report, 8-K covers material events, and Form 4 reports insider transactions. All documents link directly to SEC EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

LTGO SEC filings

Latigo Biotherapeutics SEC filings
FiledFormDescriptionDocument
Sep 3, 20268-KResults of Operations and Financial ConditionView on EDGAR
Sep 3, 202610-QQuarterly reportView on EDGAR
Aug 18, 2026SCHEDULE 13GBeneficial ownership report (passive)View on EDGAR
Aug 17, 2026SCHEDULE 13DBeneficial ownership report (activist)View on EDGAR
Aug 17, 2026SCHEDULE 13GBeneficial ownership report (passive)View on EDGAR
Aug 13, 2026SCHEDULE 13GBeneficial ownership report (passive)View on EDGAR
Aug 12, 20264Statement of changes in beneficial ownershipView on EDGAR
Aug 11, 20264OWNERSHIP DOCUMENTView on EDGAR
Aug 10, 20264OWNERSHIP DOCUMENTView on EDGAR
Aug 10, 20264Statement of changes in beneficial ownershipView on EDGAR
Aug 10, 20268-KAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Other EventsView on EDGAR
Aug 10, 20264Statement of changes in beneficial ownershipView on EDGAR
Aug 10, 20264Statement of changes in beneficial ownershipView on EDGAR
Aug 7, 2026424B4ProspectusView on EDGAR
Aug 4, 2026S-1/ARegistration statement (amendment)View on EDGAR
Aug 3, 2026S-1/ARegistration statement (amendment)View on EDGAR
Jul 17, 2026S-1Registration statementView on EDGAR

Related